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Summary.-When purified fibre and hexon proteins of adenovirus 12 were given
intramuscularly to 4-week-old BALB/c mice(250-300 jig/mouse)2 hprior to inocula-
tion with mouse sarcoma virus (0.05 ml of 104 FFU/ml) at the same site, significant
suppression of tumour growth (P < 0-001), and rapid regression in tumour size
(P < 0 001) were noted. As a rule, the survival rate in treated mice was also sig-
nificantly higher than in untreated mice. Furthermore, the disease process in
treated mice as compared to untreated mice was far less extensive as judged by the
scarcity of sarcoma lesions on the spleens. Preliminary evidence suggested that
treatment with fibre could lead to increased cellular immunity in mice. Whether
this maybe a secondary consequence ofevents wherebyfibreinhibitedtumourgrowth
rather than first order mechanism of the inhibition is not known.
A REPORT from this laboratory showed
that purified fibre and hexon proteins
of a human adenovirus (type 2) could
inhibit cell transformation by simian
adenovirus type 7 (SA-7) without altering
cell growth (Long and Khoobyarian,
1973). Similarly, a significant inhibition
of cell transformation byMoloneysarcoma
virus (MSV-M) was produced by both
proteins (Abid and Khoobyarian, 1974).
Because of these findings it seemed
feasible to undertake studies to determine
whether these proteins would influence
the induction of viral neoplasia in vivo.
Therefore, we followed the development
as well as the regression of MSV-induced
tumours in BALB/c mice pretreated with
fibre or hexon proteins, and assessed
the cellular immune status of the treated
mice by adoptive immunotherapy. The
data will demonstrate that a single dose
of these proteins, particularly fibre, re-
duces significantly the mean tumour size
of animals inoculated with MSV, causes
rapid and complete tumour regression in
all animals, and finally increases signifi-
cantly the number of survivors, an ob-
servation not reported thus far for a
purified viral protein. Although the
effects of these proteins may be mediated
through antiviral mechanisms, in this
paper we provide evidence indicating that
treatment with fibre did result in increased
cellular immunity in mice.
MATERIALS AND METHODS
Mice.-Male BALB/c mice (Carworth
farms, Carworth, New Jersey) aged 4 weeks
were used exclusively in these studies.
Virus.-A pool of Moloney strain of
murine sarcoma virus (MSV-M) prepared
by differential centrifugation (Blumenschein
and Moloney, 1969) was used.
Purification of adenovirus-12 structural
proteins.-A modification of the method
employed previously (Long andKhoobyarian,
1973) was used to purify fibre and hexon
proteins of Adl2. The procedure used to
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infect stock cultures with Adl2 and the
extraction of viral protein from infected
cultures were essentially the same as de-
scribed previously (Long and Khoobyarian,
1973). Briefly, the extracted viral proteins
were dialysed against 0-01 M phosphate
buffer at pH 7-1 for at least 24 h at 4°C.
The dialysate was centrifuged at 10,000
rev/min for 1 h before it was applied on a
microgranular (DE-32) 0-(diethylaminoethyl)
(DEAE)-cellulose column. A linear gradient
of 0-0-35 M NaCl in 0-01 M phosphate
buffer at pH 7-1 was applied through a
peristaltic pump (0-25 ml/min). The protein
peaks were monitored on an ISCO Model
UA-2 UV analyser. The eluants representing
each protein peak were pooled and the
protein concentration was determined by
u.v. absorbance at 280/260 nm in a Beckman
Model DU Spectrophotometer. The protein
fractions were identified on Ouchterlony
immunodiffusion using monospecific antisera.
The hexon and fibre proteins were eluted
at 0 05 M and 0-14 M NaCl, respectively.
These fractions were rechromatographed on
microgranular DEAE-cellulose (DE-32) using
stepwise gradient of NaCl. Rechromato-
graphed hexon and fibre proteins were
checked once more by the Ouchterlony
immunodiffusion test in order to confirm
their identity. Their protein concentration
was again determined as described above.
The purity of the proteins were then moni-
tored by gel electrophoresis (Reisfeld and
Small, 1966). The fibre and hexon prepara-
tions were adjusted to the equivalent of
1 x medium by the addition of 10 x medium
199 containing antibiotics.
Polyacrylamide gel electrophoresis.-Poly-
acrylamide disc electrophoresis wNas done
at pH 8-4 in a discontinuous buffer system
(Reisfeld and Small, 1966). The viral pro-
tein preparation was made up to 10%
with crystalline sucrose (Maizel, 1961). Bro-
mothymol blue was added as a marker.
The protein samples (about 100 jug) were
layered over a 12 cm column of 7.50% re-
solving polyacrylamide gel (acrylamide-bis-
acrylamide; 30: 0-8 in Tris-HCl buffer,
pH 8.4) and an upper stacking gel (acryl-
amide-bis-acrylamide; 10 2 5 in Tris-HCl
buffer, pH 8 4). Electrophoresis was per-
formed for 2-3 h with 3 mA/gel in 0-1 M
Tris-glycine buffer, pH 8-4. The gels were
stained for 2 h with 0.25% coomassie
brilliant blue in a mixture of methanol:
acetic acid: water in a ratio of 456: 10: 45
to visualize the protein bands.
Tumour induction in mice.-BALB/c mice
were injected intramuscularly in the right
hind leg with 0 05 ml of 1.0-3-0 x 104
FFU/ml of MSV. The diameter of the
injected leg was measured daily in order
to assess the time-course of tumour growth
and regression. In our hands, mice infected
with such an inoculum usually developed
progressive tumours (average diameter:15-0-
15-5 mm) within 10-12 days of injection.
Preparation of spleen cells.-Spleens were
removed aseptically from treated and un-
treated mice, minced, and then expressed
through sterile stainless steel mesh screens
into a small amount of Hanks' balanced
salt solution. The collected cells were cen-
trifuged at 2000 rev/min, washed twice in
Hanks' solution, and then counted for
viability by trypan blue exclusion test.
The final cell suspension was adjusted to
give 5 0 x 106 cells/0-2 ml before injecting
into mice.
RESULTS
Effect of fibre and hexon proteins on
MSV-induced tunmours. Prior to conduct-
ing this experiment, the homogeneity
of fibre and hexon proteins on poly-
acrylamide gel and their identity by an
immunodiffusion test was established.
As can be seen from Fig. 1, both proteins
appear as single bands, thus suggesting
their relative purity.
In this experiment, groups of 12-13
BALB/c mice were inoculated intra-
muscularly with fibre or hexon protein
(200-300 ,ug/injection) at various times
before and/or after inoculation with MSV
at the same site. The MSV inoculum
selected (0.05 ml of 104 FFU/ml) pro-
duced tumours in 100% of the inoculated
animals. The untreated control animals
received tissue culture medium before
inoculation of MSV in the same site.
In repeated experiments the best results
were obtained when mice were treated
with only one dose (250-300 ,ug) of viral
protein 2 h prior to MSV infection. As
shown in Fig. 2, not only was the time
of tumour growth in treated groups
delayed by 3-4 days, but the mean
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FIG. 1. Polyacrylamide gel electrophoresis
of pturifiecd fibre, and( hexon protoins of
adenovirus 12. Protein samples wvere
solubilizedl in 10% sucrose (w/v) and a(ld(le
at the top of the gel as in Fig. Electro-
phoresis was ri-n in 0 1 At Tris-glycinie
buffer pH 8 4 as (lescribed in Materials
and AMethods. The gels were stained with
coomassie blue. Gel 1: Hexon (H); gel 2:
Fibre (F); AMarker: (M).
Fie. 2. Effect of adenovirus-12 fibre and
hexon pr oteins on MSV-induced tumours
in BALB/c mice. Separate groups of
mice (12/group) were treated with 250,ug
of either protein 2 h prior to MSV inocula-
tioIn. The mean tumour size of fibre-
an(l hexon-treated mice are represented
by broken and dotted lines, respectively.
Solid line represents the mean tumour
size of controls. Mice dying during ex-
perimental period were excluded from data
presented here.
tumour size in both treated groups during
the entire period of tumour growth was
significantly reduced as compared to
untreated controls (P < 0 001). Al-
though the tumours of treated and un-
treated groups began to regress on day
12, there was also a significant difference
between the mean tumour size particularly
of fibre-treated and untreated controls
during the entire period of regression
(P < 0-001). In fact, the tumours of
fibre-treated animals regressed in much
shorter time than did those of untreated
group; by Day 28 virtually all animals
in this group had completely regressed
tumours (average diameter 5 0 mm). As
shown in Table I (Experiment 1), the
mortality rate in the untreated group
was also significantly higher than in the
treated group. As early as 14 days after
MSV infection, 30% of the untreated
mice died with progressively growing
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TABLE I. Incidence ofTumour Formation and Regression and Survival Rates in BALB/c
Mice Treated with Fibre and Hexon
lILCi(lence
of
Treat- tuimour
mneit (%)
Control 12/13(92)
Fibre 7/12(58)
Day 7 Day 14 Day 35 or 301 _ A KA
Incidence Incidence
% of % of 0
P* Sur- tumour P* Sur- tumour P* Sur-
values vivors (0 °0) values vivors (%o) values vivors
100 9/9(100) 69 5/5(100) 38
0-05 100 11/12(91) N.S.t 100 0/12(0) <0-001 100
(250 lig)
Hexon 7/12(58) 0 05 100 11/12(91) N.S. 100
(250 rig)
3/10(30) <0-001 58
2 Control
Fibre
(300 ,Lg)
10/12(83)
4/12(33) <0 005
100 12/12(100)
100 8/12(66)
* Determined by x2.
t N.S. = iot significant.
I Days 35 anid 30 apply to experiment 1 and 2, respectively.
tumours, and another 300o died during
the ensuing days, whereas no deaths
occurred in the treated groups. By Day
35, the survivor rates for untreated con-
trols, fibre-treated, and hexon-treated
mice were 38%, 1000o and 58% re-
spectively. Of particular interest was
the observation that treatment with fibre
resulted in 100% tumour regression and
with hexon in 58%. By Day 68 there
were 91% survivors in the fibre-treated
group, 500o in the hexon-treated, but
only 23% in the control group. Although
no specific assays were run to measure
spleen enlargement, more evidence of
disease in control than in fibre-treated
animals was found at autopsy. Spleno-
megaly was more prominent in control
than in fibre-treated animals at Day 68.
The number of sarcoma lesions on the
spleens of untreated animals appeared
to increase as tumours regressed, whereas
these lesions appreciably decreased in
fibre-treated animals during and after
tumour regression. When a different
batch of fibre was used in a second but
similar experiment, while all 12 animals
of the treated group had completely re-
gressed tumours by Day 30, 78%0 of
the untreated group still had tumours at
this day (Table I, Experiment 2). The
treatment of mice with two doses of fibre
(250 upg/dose) given 2 h before and 72 h
after MSV infection did not lead to
further suppression of tumour growth
when compared to those given only one
dose 2 h before MSV (Table II). On the
other hand, mice given one dose of
denatured fibre (heated at 100°C for
3 min) or given as many as four injections
of fibre 2, 12, 48 and 96 h after injection
of MSV developed tumours like those
induced in untreated controls.
Effect of fibre treatment at different
sites on MSV-induced tumours. As shown
in Fig. 3, tumours in mice given a single
dose of fibre (300 ,tg) on the opposite
site of MSV inoculation grew in size as
those in untreated MSV controls, sug-
gesting that a local action by fibre was
essential for tumour inhibition. It should
also be noted that there was again
significant reduction in mean tumour size
in treated (at the site of MSV inoculation)
and untreated mice during growth
(P 0 008 for Day 6; P = 0012 for
Day 7; P= 003 for Day 11) and the
latter part of regression periods (P
0 05 for Days 26-30), thus confirming
our previous finding.
Effect of fibre on cell-mediated immun-
ity.-Since there was a rapid regression
of tumours in fibre-treated animals, it
was thought that treatment with fibre
could have increased the host's immune
response to tumour antigens. To test
Experi-
ment
nfo.
0-05
100 7/9(78)
100 0/12(0)
75
<0001 100
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TABLE II. Treatment of BALB/c Mice with Fibre Protein Before or After MSV
Inoculation
Experiment Time of treatment
no. (h)
-2
-24
-2, +72
+2, +12, +48, +96
Number of
injections
1
1
2
4
MIean maximum tumour size
(mm+S.D.)
Control Treate(d
15 -00 8 (12) 12-1+2-7 (12)
12 -4±1-2 (12) 12-3±1]1 (12)
l3-0± 1-4 (12) 10-4±2-3 (12)
15-0-E-0-8 (12) 13-1 1-9 (12)
2t -2 1 12-5±1-4 (10) 8-6±2-3 (10) <0-01
* Mlice were injected intramuscularly into the left leg with 250 ,ig of purified fibre either before or after
MSV inoculation (0 -05 ml of 1 0-3-0 x 104 FFU/ml) at the same site. Number of animals are given
in parenthesis.
t Control mice received heated fibre (100°C, 3 min, equivaleiit to 300 pig) prior to inoculation with
MSV.
14-
12-
6 10 14 18 22 26 30
DAYS AFTER MSV(M) INOCULATION
FIG. 3. Development of M1SV-induced tu-
mours in BALB/c mice treated with fibre
at two different sites. Separate groulps
of mice (12/group) were injectedt with ap-
proximately 300 ,ug of fibre at the site of
MSV inoculation (right leg) and the
opposite site of MISV inoculation (left
leg). Broken line represents the mean
tumour size of MSV control animals;
solid and dlotted line represent the mean
tumour size of left-leg and right-leg
fibre-treated MSV infected mice, re-
spectively.
this hypothesis, groups of 12 mice were
inoculated intraUperitoneally with 5 x 106
spleen cells obtained from: (1) untreated
mice 15 days after MSV inoculation, (2)
fibre-treated mice 15 days after MSV
infection, (3) untreated mice 30 days
after MSV inoculation, (4) fibre-treated
mice 30 days after MSV inoculation, and
(5) normal syngeneic mice. After 7 days,
all groups were challenged intramuscu-
larly with MSV (0.05 ml of 104 FFU/ml),
and the development and incidence of
tumours was observed. As can be seen
from Fig. 4, mice given 15-day spleen
cells from fibre-treated donors not only
developed significantly smaller tumours
(P < 0*03 to P < 04001 compared to
controls), but the tumours also regressed
more rapidly and completely than those
receiving 15-day spleen cells from un-
treated MSV controls. As shown in
Table III, only 25% (3/12) of the animals
receiving spleen cells from treated donors
developed tumours in 13 days (peak
growth period) as compared to 9200
(11/12) for the group receiving spleen
cells from untreated MSV controls
(P < 0.01). By Day 29, 82% (9/11) of
recipients of the control spleen cells still
had tumours as compared to 8% (1/12)
of recipients of the treated spleen cells
(P < 0 001). On the other hand, only
l/12 recipients of 30-day spleen cells
from treated donors developed a small
tumour (6-0 mm) on Day 24, and re-
gressed by Day 29, whereas 5000 (6/12)
of recipients of 30-day spleen cells from
untreated MSV donors had tumours by
Day 13 (P < 0.05) and in only 34%o of
these animals did tumours completely
regress by Day 38. Nevertheless, only
on Days 11 and 13 was there a significant
reduction in mean tumour size ofrecipient
of 30-day spleen cells from treated
donors relative to recipients of 30-day
I
*
P (t test)
0-002
>0-5
0-007
>0-5
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TABLE III.-Incidence of MSVTnmours in Mice Inoculated withSpleen Cellsfrom Fibre-
treated and Untreated MSV-infected Mice
Donor mice*
Treatment Infecting
with virus
None MSV
Fibre MSV
None MSV
Fibre MSV
None None
Recipient mice
Inoculated with
15-day spleen cells
15-day spleen cells
30-day spleen cells
30-day spleen cells
Normal spleen cells
Challenged
7 days
later with
MSV
MSV
MSV
MSV
MSV
Maximum
incidence of
tumour (%)
11/12 (92) -
3/12 (25) f
6/12 (50)
1/12 (8) f
12/12 (100)
P values
(from x2)
<0-01
<0-05
* Mice were treated with a single dose of fibre (250 *sg) 2 h prior to infection with MSV (0 05 ml of
104 FFU/ml).
5 have equally greater protective effect
1 against MSV tumours is not yet known.
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FIG. 4.-Development of MSV-induced tu-
mours in BALB/c mice treated with
spleen cells from fibre-treated and un-
treated MSV-infected mice. Mice were
inoculated with: normal spleen cells (open
circles); 15-day spleen cells from untreated
MSV controls (solid circles); 15-day spleen
cells from fibre-treated MSV-infected mice
(open triangles); 30-day spleen cells from
untreated MSV controls (solid squares);
and 30-day spleen cells from fibre-treated
4SV-infected mice (open squares). The
difference between mean tumour size
in mice treated with 15-day spleen cells
from fibre-treated animals and that in
mice treated with 15-day spleen cells from
untreated mice had P ranging from <0 03
to P<0*001 for Day 7 to Day 25.
Only for Days 11 and 13 did mean tumour
size in mice receiving 30-day spleen cells
from fibre-treated as compared to un-
treated mice have P = 0 016 and P = 0 04,
respectively.
spleen cells from untreated MSV donors
(P = 0.01, P = 0-04) (Fig. 4). Whether
the serum of fibre-treated animals would
DISCUSSION
The data presented here show that
the growth of virus-induced mouse sarco-
mata in 4-week-old BALB/c mice can
be significantly suppressed if a single
dose of purified adenovirus fibre or hexon
protein is given 2 h before inoculation
with MSV at the same site. The de-
natured fibre, however, is ineffective in
suppressing tumours and we interpret
this as meaning that biologically active
fibre is required for tumour suppression.
On the other hand, a single injection of
fibre given 24h before MSV infection,
or multiple injection of fibre made after
MSV infection were also ineffective. The
basis for this finding is not known.
A strong possibility exists that these
proteins may act locally by limiting the
amount of viral replication at the site
of inoculation prior to tumour develop-
ment or even in virus-synthesizing tumour
cells during the process of tumour growth.
This may be true, since injection of fibre
at one site and MSV at the opposite site
did not inhibit tumour growth. If viral
suppression occurred at the local site, the
amount of virus available for infection
of principal organs would be limited and
hence the outcome of oncogenesis would
be altered. Compatible with this idea
is the fact that we have seen little evidence
of disease process in the spleens of
fibre-treated animals (very few sarcoma
lesions with virtually no splenomegaly)
Groups
1
2
3
4
5
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as opposed to those in untreated MSV
controls which had abundant lesions and
larger spleens. However, more direct
evidence must be obtained before further
conclusions can be drawn. A second
possibility is that inhibition of tumour
might be due to enhancement of a local
inflammatory response which could in-
hibit not only virus replication and
tumour cell growth but also accelerate
cellular immune responses. If this were
the case, one might expect greater in-
flammatory response in treated than in
untreated animals. This possibility has
not yet been examined.
Giuliani, Casazza and Dimarco (1973)
and Pollack and Nelson (1973) have
shown that lymphoid cells of mice in
which MSV-induced tumours had re-
gressed have the capacity to passively
protect newborn and immunodepressed
young mice from developing tumours
when challenged with MSV. Since there
was a rapid and complete regression of
tumours in all fibre-treated animals,
adoptive transfer of spleen cells in vivo
was used to determine whether increased
cell-mediated immune reaction was opera-
tive in these animals. Preliminary evi-
dence indicated that spleen cells from
fibre-treated animals carrying medium
size tumours (average 9-5 mm) could
significantly reduce the size of primary
sarcomata (P < 0 01 relative to controls)
as well as the frequency of tumour de-
velopment in syngeneic mice (P < 0 01
to P < 0-001 compared to controls).
Likewise, spleen cells from fibre-treated
animals in which tumours had completely
regressed were more effective in trans-
ferring immunity against primary MSV-
induced tumours than those from com-
parable MSV controls. However, we do
not know which subpopulation(s) of lym-
phocytes might play the most important
role in inhibiting tumour growth. Further-
more, whether or not the anti-tumour
humoral response of the treated animals
might also be affected is not known.
Finally, it is possible that interactions
among cellular and humoral factors as
well as intercellular reactions may to-
gether be involved in the suppression of
tumour in this system. These questions
are now under investigation.
This study was supported by a re-
search grant from the American Cancer
Society, Inc. (74-5 Ill. Division).
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